After a long period of prohibition, the FDA has granted psilocybin “breakthrough” status for the treatment of mental disorders. Distinguished medical institutions, ranging from John Hopkins University to the New York University’s Langone Medical Center and Imperial College in London, have produced research that has been widely published and even more widely hailed.
The interest and momentum are well founded. The current COVID-19 crisis reveals significant disparities between mental health needs and mental health resources. Yet, there is evidence-based science that tells us that psilocybin can make a difference. Peer reviewed clinical studies have determined that psilocybin reduces the symptoms of psychological trauma, PTSD, depression, anxiety, stress and addiction.